About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

New approaches beckon for small cell lung cancer treatment

Big Idea Ventures announces cohort of 17 start-ups

FDA fast tracks Immutep non-small cell lung cancer candidate

New biotech company aims to bridge gap between stem cell research and athletic injuries

Transcenta monoclonal antibody gets FDA clearance

OncoSec slashing staff numbers to prioritize pipeline

ADVERTISEMENT

Intravacc to develop intranasal gonorrhea vaccine with $14.6M NIH/NIAID contract

CanSinoBIO to present latest data on inhaled COVID vaccine

Araris Biotech closes $24M financing round for ADCs

TrialSpark partners with Sanofi to acquire and develop clinical-stage novel therapies

ASPIRE set up to collaborate on amyloidosis

Aeglea BioTherapeutics updates homocystinuria program

ADVERTISEMENT